BSGM - BioSig Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.95
-0.28 (-3.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.45
Open6.50
Bid6.87 x 1000
Ask6.95 x 2900
Day's Range6.99 - 7.23
52 Week Range1.42 - 7.88
Volume142,767
Avg. Volume71,370
Market Cap130.793M
Beta (3Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-1.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    BioSig Technologies Completes Private Placement

    BioSig Technologies, Inc. (NASDAQ: BSGM), today announced the closing of a private placement of the Company’s common stock for gross proceeds of approximately $8,620,506. The offering was exempt from registration under Section 4(a)(2) of the United States Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated by the U.S. Securities and Exchange Commission (“SEC”) thereunder. BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace (www.biosig.com).

  • ACCESSWIRE7 days ago

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • GlobeNewswire11 days ago

    BioSig Technologies to Present at the LD Micro Virtual Conference

    BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, announced today that they will be presenting at the second annual LD Micro Virtual Conference on Wednesday, March 13, 2019 at 2pm EST, 11am PT. Mr. Kenneth Londoner, Founder, Chairman & CEO of BioSig Technologies, Inc., will be giving the presentation and answering questions from investors.

  • GlobeNewswire12 days ago

    BioSig Technologies to Present at the 31st Annual ROTH Conference

    BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that the Company will present at the 31st Annual ROTH Conference. The conference is being held at The Ritz Carlton, Laguna Niguel in Orange County, CA, on March 17-19, 2019.

  • GlobeNewswire13 days ago

    BioSig Appoints Barry Keenan as Vice President of Engineering

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company appointed Dr. Barry Keenan, Ph.D, MBA, PMP to head up BioSig’s advanced product development. Dr. Keenan brings to the Company over 20 years of experience in R&D, product development and commercialization and deep industry expertise in a range of sectors, including neuromodulation, deep brain stimulation, sensing, imaging and cardiac pacing.

  • GlobeNewswire21 days ago

    BioSig Announces Expansion of Engineering Team

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company appointed a Senior R&D Engineer and is working on further senior biomedical engineering hires to support BioSig’s growing manufacturing processes and advanced R&D activities. Mr. Fui Veavea brings to the Company over 29 years of manufacturing and engineering experience in a range of medical device sectors, including implantable class III devices, diabetes-monitoring and respiratory diagnostic systems.

  • GlobeNewswire26 days ago

    The Future Is Now; Med Tech That’s Changing Lives

    Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality. BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.

  • GlobeNewswire27 days ago

    BioSig Announces Successful First-In-Human Use of PURE EP System

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company successfully conducted first patient cases using PURE EP(tm) System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX. The patient studies were conducted by Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.

  • GlobeNewswirelast month

    BioSig Technologies Inc. Issues 2019 Shareholder Letter

    BioSig Technologies, Inc. (BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has issued their February 2019 letter to its shareholders, highlighting their recent uplisting to the Nasdaq Capital Market, commercialization efforts, their relationships with world renowned medical centers and strategic goals moving forward. Successfully raised a total of $13.5 million of capital, to finance upcoming operational milestones.

  • GlobeNewswirelast month

    BioSig Appoints John Kowalski to Lead Commercialization of PURE EP

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has appointed Mr. John Kowalski as Vice President of Sales. Mr. Kowalski brings to the Company over 30 years of experience in medical device sales, including over 20 years at Biosense Webster, a Johnson & Johnson company.

  • Have Insiders Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares?
    Simply Wall St.2 months ago

    Have Insiders Been Buying BioSig Technologies, Inc. (NASDAQ:BSGM) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...

  • GlobeNewswire3 months ago

    Johnson & Johnson's Biosense Webster’s MaryAnn Edzards Joins BioSig

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has appointed Mrs. MaryAnn Edzards as Senior Director - Account Manager. Mrs. Edzards brings to the Company over 10 years of experience in electrophysiology (EP), including six years at Biosense Webster, a Johnson & Johnson company.

  • Moving Average Crossover Alert: Biosig Technologies, Inc.
    Zacks3 months ago

    Moving Average Crossover Alert: Biosig Technologies, Inc.

    Biosig Technologies could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

  • GlobeNewswire3 months ago

    BioSig Technologies To Commence First–in-Human Studies at Mayo Clinic

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Mayo Clinic to conduct First-in-Human studies using the PURE EP™ System. Mayo Clinic has conducted twelve pre-clinical studies to date using the PURE EP™ System, results of which have been published in a number of journals, including The Journal of Innovations in Cardiac Rhythm Management.

  • Could The BioSig Technologies Inc (NASDAQ:BSGM) Ownership Structure Tell Us Something Useful?
    Simply Wall St.4 months ago

    Could The BioSig Technologies Inc (NASDAQ:BSGM) Ownership Structure Tell Us Something Useful?

    Every investor in BioSig Technologies Inc (NASDAQ:BSGM) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...

  • GlobeNewswire4 months ago

    BioSig Technologies Signs Agreement with Texas Cardiac Arrhythmia Institute for First–in-Human Studies

    BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in Austin, Texas to conduct First-in-Human studies using the PURE EP™ System.

  • GlobeNewswire4 months ago

    BioSig Technologies Announces New Research Program with Mayo Clinic

    The new program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. The program will consist of a number of two-to three-year projects, which will focus on development of additional advanced features of PURE EP(tm) System within the field of electrophysiology and potential clinical applications of BioSig’s technology in a new, previously unexplored, field.

  • GlobeNewswire4 months ago

    BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018

    Santa Monica, CA, Nov. 12, 2018 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal.

  • GlobeNewswire5 months ago

    BioSig Technologies Opens Business Office in Norwalk, CT

    The new office will complement the Company’s headquarters in Los Angeles, CA and administration and finance office in Austin, TX. Norwalk office becomes the Company’s first location on the East Coast and will serve as the commercialization, sales support, investor relations and business development location.

  • Zacks Small Cap Research5 months ago

    BSGM: PURE EP Launch Timing Aligns Well With Attractive Market Fundamentals

    BioSig Technologies Inc. (BSGM) is a medical device company engaged in the development and commercialization of a proprietary signal processing platform designed to significantly improve real-time information and clinical decision-making in the ~$4B - $5B electrophysiology (EP) market. Following receipt of FDA 510(k) clearance in early August and subsequently uplisting their shares to Nasdaq, BioSig is readying for launch of the PURE EP System while simultaneously ramping up investor outreach efforts. In late August they hired Amy Scott, a seasoned medical device professional with more than two decades’ experience in the electrophysiology space, to lead the launch.

  • Zacks Small Cap Research6 months ago

    BSGM: PURE EP Poised For Strong U.S. Launch

    Following receipt of FDA 510(k) clearance in early August and uplisting their shares to Nasdaq, BioSig Technologies Inc. (BSGM) is readying for launch of their flagship product, the PURE EP System, and simultaneously ramping up investor outreach efforts. BioSig is a medical device company engaged in the development and commercialization of a proprietary signal processing platform designed to significantly improve real-time information and clinical decision-making in the ~$4B - $5B electrophysiology (EP) market. When drug therapy fails to control certain complex heart conditions such as atrial fibrillation and ventricular tachycardia, cardiologists often turn to catheter ablation.